40
Registered trials
19
Recruiting
12
Completed trials
1
Countries active
72
Unique IMPs
100%
Results reported
Oversight events:
4 temporary halts
1 urgent safety measure
1 unexpected event
1 corrective measure
across 5 trials
View oversight register →
100%
12 of 12 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).
Top indications
Gastroenteropancreatic neuroendocrine tumour disease
1
Lung transplant
1
Ovarian epithelial cancer
1
Sarcoidosis
1
Thymic carcinoma
1
Allogenic stem cell transplantation
1
Arrhythmogenic right ventricular dysplasia
1
Cerebral palsy
1
Limbal stem cell deficiency
1
Ovarian cancer metastatic
1
Renal failure
1
Systemic lupus erythematosus
1
Top IMPs
DOMVANALIMAB
2
NINTEDANIB
2
SODIUM CHLORIDE
2
ZIMBERELIMAB
2
(1-(111C)METHYLPIPERIDIN-4-YL)METHYL 5-AMINO-6-CHLORO-1,4-BENZODIOXINE-8-CARBOXYLATE
1
[18F]-ALTANSERIN
1
[18F]CPFPX
1
1-[[(3S)-2,3-DIHYDRO-1,4-BENZODIOXIN-3-YL]METHYL]-4-[3-((11C)METHOXYMETHYL)-2-PYRIDINYL]PIPERAZINE
1
4-FLUORO-N-[2-[4-(2-METHOXYPHENYL)PIPERAZIN-1-YL]ETHYL]-N-PYRIDIN-2-YLBENZAMIDE
1
ABACAVIR, LAMIVUDINE
1
BEFIRADOL (18F)
1
BOTULINUM TOXIN TYPE A
1
All trials
40 totalShowing 1–24 of 40 trials